First-year efficacy of 3.75 mg versus 11.25 mg depot leuprolide acetate and predictors of biochemical non-suppression in girls with central precocious puberty

Objective

To compare first-year biochemical and auxological outcomes of monthly 3.75 mg and 3-monthly 11.25 mg depot leuprolide acetate (dLA) treatment in girls with central precocious puberty (CPP) and to evaluate factors associated with biochemical non-suppression and first-year growth velocity.